Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI0GMB)

• Drug Name: 5-hydroxyindole Drug Info
• Synonyms: 5-Hydroxyindole; 1H-Indol-5-ol; 1953-54-4; INDOL-5-OL; 5-Hydroxy-1H-indole; Hydroxy-5 indole; 5-Indolol; UNII-320UN7XZYN; Hydroxy-5-indole; Hydroxy-5 indole [French]; CCRIS 4422; 5-Hydroxyindole, 97%; EINECS 217-782-6; MFCD00005677; NSC 87503; BRN 0112349; 320UN7XZYN; CHEBI:89649; LMIQERWZRIFWNZ-UHFFFAOYSA-N; NSC-87503; 5-hydroxy-indole; Hydroxy-5 indole [French]; 5-hydroxylindole; 5-hydroxy-indol; 5-hydroxy indole; 3fuh; 5H1; zlchem 359; 5Hydroxy-1H-indole; PubChem7263; 1-H-indol-5-ol; 1H-indol-5-ol.; 4b3c; ACMC-1BQT3; WLN: T56 BMJ GQ

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 16054
  ChEBI ID: CHEBI:89649
  CAS Number: CAS 1953-54-4
  TTD Drug ID: DMI0GMB

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 3A receptor (HTR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dolasetron	DMMG26Z	Nausea	MD90	Approved	[4]
Alosetron	DML2A03	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[5]
Tropisetron	DMNSJ7V	Fibromyalgia	MG30.01	Approved	[6]
Palonosetron	DMBHMOX	Nausea	MD90	Approved	[7]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[6]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[8]
Cilansetron	DMP0NGX	Irritable bowel syndrome	DD91.0	Phase 3	[9]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[10]
Norcisapride	DMJSKUI	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[11]
YM-114	DML2IXO	Nausea	MD90	Discontinued in Phase 2	[12]

Drug(s) Affected By Sulfotransferase 1A1 (SULT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[14]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[3]
Benzyl alcohol	DMBVYDI	Head and body lice	1G00.0	Approved	[15]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[3]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[16]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[17]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[19]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[20]

Drug(s) Affected By Sulfotransferase 1A3 (SULT1A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[23]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[24]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[25]
Vitamin C	DMXJ7O8	Adenocarcinoma	2D40	Approved	[26]
Benzyl alcohol	DMBVYDI	Head and body lice	1G00.0	Approved	[15]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[3]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 3A receptor (HTR3A)	TTPC4TU	5HT3A_HUMAN	Modulator (allosteric modulator)	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Sulfotransferase 1A1 (SULT1A1)	OT0K7JIE	ST1A1_HUMAN	Biotransformations	[3]
Sulfotransferase 1A3 (SULT1A4)	OTHJ8WWV	ST1A3_HUMAN	Biotransformations	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2295).
• [2] The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor. J Biol Chem. 2008 Mar 14;283(11):6826-31.
• [3] Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab Dispos. 2001 Mar;29(3):274-81.
• [4] Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
• [5] Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
• [6] Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
• [7] Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
• [8] Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
• [9] Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
• [10] Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
• [11] mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
• [12] Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
• [13] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [14] Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
• [15] Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
• [16] Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
• [17] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [18] Methotrexate induction of human sulfotransferases in Hep G2 and Caco-2 cells. J Appl Toxicol. 2005 Sep-Oct;25(5):354-60.
• [19] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [20] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [21] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [22] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [23] Solvent effect on cDNA-expressed human sulfotransferase (SULT) activities in vitro. Drug Metab Dispos. 2003 Nov;31(11):1300-5.
• [24] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [25] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [26] Megadose vitamin C suppresses sulfoconjugation in human colon carcinoma cell line Caco-2. Toxicol In Vitro. 2011 Mar;25(2):500-4.